A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia

被引:118
作者
Ascher-Svanum, Haya
Zhu, Baojin
Faries, Douglas
Lacro, Jonathan P.
Dolder, Christian R.
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[4] Wingate Univ, Sch Pharm, Wingate, NC USA
关键词
D O I
10.4088/JCP.v67n0715
中图分类号
B849 [应用心理学];
学科分类号
040203 [应用心理学];
摘要
Objectives: This study aimed to prospectively identify the best single predictor and the best set of predictors of risk for nonadherence with antipsychotic medication in the treatment of patients with schizophrenia. Method. We used data from 1579 patients in a 3-year, prospective, naturalistic, nonrandomized, multisite study of schizophrenia patients conducted from July 1997 to September 2003 (U.S. Schizophrenia Care and Assessment Program). Adherence with any oral antipsychotic medication was assessed using patient-reported medication adherence and an indirect adherence measure based on medical record prescription information. Patients who reported poor medication adherence or had a medication possession ratio : 80% (percentage of days with prescriptions for any oral antipsychotic) during the first year after enrollment were defined as nonadherent (N = 296, 18.8%). Thirty-nine previously reported potential risk factors of nonadherence with antipsychotic medication were assessed at enrollment with valid and reliable measures. Risk factors represented patient-, environment-, and treatment-related domains, including sociodemographics, symptom severity, substance use, threat to safety of self and others, other illness-related factors, need for supervision, medication-related adverse events, and prior medication-utilization patterns. Results: The best single predictor of future nonadherence was nonadherence during the 6 months prior to enrollment (odds ratio = 4.1, 95% confidence interval = 3.1 to 5.6, p <.001). The best set of predictors of nonadherence, ordered by strength of association, included prior nonadherence, recent illicit drug use, recent alcohol use, prior treatment with antidepressants, and greater patient-reported, medication-related cognitive impairment. Conclusion: Nonadherence with antipsychotic medication is associated with a well-defined set of risk factors that can be used to identify patients who are predisposed to poor adherence.
引用
收藏
页码:1114 / 1123
页数:10
相关论文
共 43 条
[1]
Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications [J].
Al-Zakwani, IS ;
Barron, JJ ;
Bullano, MF ;
Arcona, S ;
Drury, CJ ;
Cockerham, TR .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (07) :619-626
[2]
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care [J].
Ascher-Svanum, H ;
Faries, DE ;
Zhu, BJ ;
Ernst, FR ;
Swartz, MS ;
Swanson, JW .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (03) :453-460
[3]
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia [J].
Ascher-Svanum, Haya ;
Zhu, Baojin ;
Faries, Douglas ;
Landbloom, Ron ;
Swartz, Marvin ;
Swanson, Jeff .
BMC PSYCHIATRY, 2006, 6 (1)
[4]
BLOMHOFF S, 1990, HOSP COMMUNITY PSYCH, V41, P771
[5]
A 2-YEAR PROSPECTIVE-STUDY OF TREATMENT COMPLIANCE IN PATIENTS WITH SCHIZOPHRENIA [J].
BUCHANAN, A .
PSYCHOLOGICAL MEDICINE, 1992, 22 (03) :787-797
[6]
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia [J].
Byerly, M ;
Fisher, R ;
Whatley, K ;
Holland, R ;
Varghese, F ;
Carmody, T ;
Magouirk, B ;
Rush, AJ .
PSYCHIATRY RESEARCH, 2005, 133 (2-3) :129-133
[7]
Medication adherence of individuals with a first episode of psychosis [J].
Coldham, EL ;
Addington, J ;
Addington, D .
ACTA PSYCHIATRICA SCANDINAVICA, 2002, 106 (04) :286-290
[8]
Compliance with medication regimens for mental and physical disorders [J].
Cramer, JA ;
Rosenheck, R .
PSYCHIATRIC SERVICES, 1998, 49 (02) :196-201
[9]
Awareness of illness in schizophrenia and outpatient treatment adherence [J].
Cuffel, BJ ;
Alford, J ;
Fischer, EP ;
Owen, RR .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1996, 184 (11) :653-659
[10]
The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: Combined results of the North American and international trials [J].
Davis, JM ;
Chen, N .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (10) :757-771